Article Text

Paraneoplastic opsoclonus-myoclonus associated with renal cell carcinoma and responsive to tumour ablation
  1. M C VIGLIANI,
  2. L PALMUCCI,
  3. P POLO,
  4. R MUTANI,
  5. D SCHIFFER
  1. Dipartimento di Neuroscienze, Università degli Studi di Torino, Via Cherasco 15, 10126 Torino, Italy
  2. Department of Surgical Sciences, Section of Urology, University of Turin, Italy
  1. Dr M C Vigliani vigliani{at}usa.net
  1. S DE LUCA,
  2. A DE ZAN
  1. Dipartimento di Neuroscienze, Università degli Studi di Torino, Via Cherasco 15, 10126 Torino, Italy
  2. Department of Surgical Sciences, Section of Urology, University of Turin, Italy
  1. Dr M C Vigliani vigliani{at}usa.net

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Opsoclonus is a rare but distinctive disorder of ocular motility, characterised by irregular, continual, and conjugated chaotic saccades of the eyes. It is increased with eye closure and with fixation, and it persists during sleep. When accompanied by other symptoms of CNS involvement, such as head and appendicular myoclonus and truncal ataxia, it constitutes a striking clinical picture, known as opsoclonus-myoclonus syndrome. Opsoclonus is relatively frequent in children, but it is rare in adults. In adults, the most common aetiology is idiopathic, accounting for about 50% of cases; usually these patients are younger than 40 and have a good prognosis. The second most common cause is paraneoplastic, responsible for 20% of cases. All paraneoplastic cases reported in the literature occurred in patients over 40. The most common tumours, which give rise to 70% of described cases, are breast and lung cancers (small cell lung cancer and adenocarcinoma). Because of the nature of the underlying lesion, the great majority of these patients die in a few months.1 Whereas successful treatment of the malignancy results in a significant improvement …

View Full Text